BioSpace News Archive

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announces financial results for fiscal year ended December 31, 2019.

Syndax Pharmaceuticals, Inc. (“Syndax,” the “Company” or “we”) (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that members of its management team will participate in two upcoming investor conferences

Sutter is the first health system in the U.S. to run quality review on applicable CT lung scans; Ferrum’s AI quality platform aims to reduce medical errors across the patient journey [18-February-2020] SAN FRANCISCO , Feb. 18, 2020 /PRNewswire/ -- Sutter Health, a not-for profit healthcare network in Northern California , today announced the launch of Ferrum’s artifi

Stealth BioTherapeutics (Nasdaq: MITO), today announced positive results from its retrospective natural history study, clinical protocol SPIBA-001, evaluating the efficacy of subcutaneous injections of elamipretide relative to a natural history control comprised of 19 propensity score matched subjects with Barth syndrome (Barth)

Theravance Biopharma, Inc. (NASDAQ: TBPH), a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines, will webcast Management presentations

Rocket Pharmaceuticals, Inc., a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, announces participation at the following upcoming conferences

Acceleron Pharma Inc. (Nasdaq:XLRN) today announced it will host a webcast and conference call on Thursday, February 27, 2020 at 5:00 p.m. EST to discuss its fourth quarter and full year 2019 operating and financial results.

Rheos Medicines, a biopharmaceutical company harnessing insights in immunometabolism to create a new class of therapeutics for patients with severe autoimmune disorders, inflammatory diseases and cancer, today announced that Barbara S. Fox, Ph.D., the Company’s Chief Executive Officer, will present at the Cowen and Company 40th Annual Health Care Conference

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that it has achieved full enrollment in its HELIOS-A Phase 3 study of vutrisiran, an investigational RNAi therapeutic in development for the treatment of ATTR amyloidosis.

Nucleus Biologics, a leader in precision cell culture, announced today a complete line of cGMP grade media and a new supplement to enable improved insulin response and standardized processing of human pancreatic islets and beta cells.